O	0	10	Discussion	Discussion	NN	B-NP

O	11	18	Because	Because	IN	B-SBAR
O	19	28	Netherton	Netherton	NNP	B-NP
O	29	37	syndrome	syndrome	NN	I-NP
O	38	46	exhibits	exhibit	VBZ	B-VP
O	47	55	allergic	allergic	JJ	B-NP
O	56	65	phenotype	phenotype	NN	I-NP
O	65	66	,	,	,	O
O	67	69	it	it	PRP	B-NP
O	70	72	is	be	VBZ	B-VP
O	73	83	reasonable	reasonable	JJ	B-ADJP
O	84	86	to	to	TO	B-VP
O	87	96	speculate	speculate	VB	I-VP
O	97	101	that	that	DT	B-NP
O	102	108	SPINK5	SPINK5	NN	I-NP
O	108	109	,	,	,	O
O	110	115	which	which	WDT	B-NP
O	116	118	is	be	VBZ	B-VP
O	119	126	mutated	mutate	VBN	I-VP
O	127	129	in	in	IN	B-PP
O	130	139	Netherton	Netherton	NNP	B-NP
O	140	148	syndrome	syndrome	NN	I-NP
O	148	149	,	,	,	O
O	150	153	may	may	MD	B-VP
O	154	157	act	act	VB	I-VP
O	158	160	as	as	IN	B-PP
O	161	162	a	a	DT	B-NP
O	163	172	candidate	candidate	NN	I-NP
O	173	177	gene	gene	NN	I-NP
O	178	181	for	for	IN	B-PP
O	182	188	asthma	asthma	NN	B-NP
O	189	192	and	and	CC	O
O	193	198	other	other	JJ	B-NP
O	199	207	allergic	allergic	JJ	I-NP
O	208	216	diseases	disease	NNS	I-NP
O	217	218	[	[	(	O
O	218	219	9	9	CD	B-NP
O	219	220	]	]	)	O
O	220	221	.	.	.	O

O	222	224	An	An	DT	B-NP
O	225	234	extensive	extensive	JJ	I-NP
O	235	241	search	search	NN	I-NP
O	242	245	for	for	IN	B-PP
O	246	252	single	single	JJ	B-NP
O	253	263	nucleotide	nucleotide	NN	I-NP
O	264	277	polymorphisms	polymorphism	NNS	I-NP
O	278	280	in	in	IN	B-PP
O	281	284	the	the	DT	B-NP
O	285	291	SPINK5	SPINK5	NN	I-NP
O	292	295	led	lead	VBD	B-VP
O	296	298	to	to	TO	B-PP
O	299	302	the	the	DT	B-NP
O	303	317	identification	identification	NN	I-NP
O	318	320	of	of	IN	B-PP
O	321	322	a	a	DT	B-NP
O	323	329	number	number	NN	I-NP
O	330	332	of	of	IN	B-PP
O	333	337	SNPs	SNP	NNS	B-NP
O	337	338	,	,	,	O
O	339	348	including	include	VBG	B-PP
O	349	352	six	six	CD	B-NP
O	353	366	nonsynonymous	nonsynonymous	JJ	I-NP
O	367	371	SNPs	SNP	NNS	I-NP
O	372	374	in	in	IN	B-PP
O	375	381	coding	cod	VBG	B-VP
O	382	388	region	region	NN	B-NP
O	389	393	that	that	WDT	B-NP
O	394	399	might	might	MD	B-VP
O	400	407	perturb	perturb	VB	I-VP
O	408	411	its	its	PRP$	B-NP
O	412	418	immune	immune	JJ	I-NP
O	419	427	function	function	NN	I-NP
O	427	428	.	.	.	O

O	429	439	Subsequent	Subsequent	JJ	B-NP
O	440	450	genotyping	genotyping	NN	I-NP
O	451	453	of	of	IN	B-PP
O	454	459	three	three	CD	B-NP
O	460	473	nonsynonymous	nonsynonymous	JJ	I-NP
O	474	478	SNPs	SNP	NNS	I-NP
O	478	479	,	,	,	O
O	480	486	A1103G	A1103G	NN	B-NP
O	486	487	,	,	,	O
O	488	494	G1156A	G1156A	NN	B-NP
O	495	498	and	and	CC	I-NP
O	499	505	G1258A	G1258A	NN	I-NP
O	506	508	in	in	IN	B-PP
O	509	512	two	two	CD	B-NP
O	513	524	independent	independent	JJ	I-NP
O	525	531	panels	panel	NNS	I-NP
O	532	534	of	of	IN	B-PP
O	535	542	British	British	JJ	B-NP
O	543	551	families	family	NNS	I-NP
O	552	558	showed	show	VBD	B-VP
O	559	560	a	a	DT	B-NP
O	561	572	significant	significant	JJ	I-NP
O	573	584	association	association	NN	I-NP
O	585	592	between	between	IN	B-PP
O	593	596	SNP	SNP	NN	B-NP
O	597	603	G1258A	G1258A	NN	I-NP
O	604	605	(	(	(	O
O	605	614	Glu420Lys	Glu420Lys	NN	B-NP
O	614	615	)	)	)	O
O	616	619	and	and	CC	O
O	620	625	atopy	atopy	NN	B-NP
O	625	626	,	,	,	O
O	627	633	atopic	atopic	JJ	B-NP
O	634	644	dermatitis	dermatitis	NN	I-NP
O	644	645	,	,	,	O
O	646	654	elevated	elevated	JJ	B-NP
B-Organism_substance	655	660	serum	serum	NN	I-NP
O	661	664	IgE	IgE	NN	I-NP
O	665	671	levels	level	NNS	I-NP
O	672	675	and	and	CC	O
O	676	682	asthma	asthma	NN	B-NP
O	683	684	[	[	(	O
O	684	686	10	10	CD	B-NP
O	686	687	]	]	)	O
O	687	688	.	.	.	O

O	689	693	This	This	DT	B-NP
O	694	705	association	association	NN	I-NP
O	706	709	was	be	VBD	B-VP
O	710	719	confirmed	confirm	VBN	I-VP
O	720	722	in	in	IN	B-PP
O	723	724	a	a	DT	B-NP
O	725	730	large	large	JJ	I-NP
O	731	737	German	German	JJ	I-NP
O	738	748	population	population	NN	I-NP
O	749	752	and	and	CC	O
O	753	756	two	two	CD	B-NP
O	757	765	Japanese	Japanese	JJ	I-NP
O	766	777	populations	population	NNS	I-NP
O	778	779	[	[	(	O
O	779	781	16	16	CD	B-NP
O	781	782	-	-	HYPH	I-NP
O	782	784	18	18	CD	I-NP
O	784	785	]	]	)	O
O	785	786	.	.	.	O

O	787	791	Kato	Kato	NNP	B-NP
O	792	794	et	et	FW	I-NP
O	795	797	al	al	FW	I-NP
O	798	806	analyzed	analyze	VBN	B-VP
O	807	812	eight	eight	CD	B-NP
O	813	817	SNPs	SNP	NNS	I-NP
O	818	820	in	in	IN	B-PP
O	821	825	exon	exon	NN	B-NP
O	826	828	13	13	CD	I-NP
O	829	832	and	and	CC	I-NP
O	833	835	14	14	CD	I-NP
O	836	838	of	of	IN	B-PP
O	839	842	the	the	DT	B-NP
O	843	849	SPINK5	SPINK5	NN	I-NP
O	850	859	including	include	VBG	B-PP
O	860	866	G1258A	G1258A	NN	B-NP
O	867	868	(	(	(	O
O	868	877	Glu420Lys	Glu420Lys	NN	B-NP
O	877	878	)	)	)	O
O	878	879	,	,	,	O
O	880	883	and	and	CC	O
O	884	889	found	find	VBD	B-VP
O	890	891	a	a	DT	B-NP
O	892	900	positive	positive	JJ	I-NP
O	901	912	association	association	NN	I-NP
O	913	915	of	of	IN	B-PP
O	916	921	seven	seven	CD	B-NP
O	922	926	SNPs	SNP	NNS	I-NP
O	927	931	with	with	IN	B-PP
O	932	938	atopic	atopic	JJ	B-NP
O	939	949	dermatitis	dermatitis	NN	I-NP
O	950	952	in	in	IN	B-PP
O	953	954	a	a	DT	B-NP
O	955	963	Japanese	Japanese	JJ	I-NP
O	964	969	study	study	NN	I-NP
O	970	976	sample	sample	NN	I-NP
O	977	982	using	use	VBG	B-VP
O	983	984	a	a	DT	B-NP
O	985	989	case	case	NN	I-NP
O	989	990	-	-	HYPH	B-NP
O	990	997	control	control	NN	I-NP
O	998	1003	study	study	NN	I-NP
O	1004	1010	design	design	NN	I-NP
O	1011	1012	[	[	(	O
O	1012	1014	16	16	CD	B-NP
O	1014	1015	]	]	)	O
O	1015	1016	.	.	.	O

O	1017	1023	Nishio	Nishio	NNP	B-NP
O	1024	1026	et	et	FW	I-NP
O	1027	1029	al	al	FW	I-NP
O	1030	1038	surveyed	survey	VBD	B-VP
O	1039	1043	five	five	CD	B-NP
O	1044	1046	of	of	IN	B-PP
O	1047	1050	six	six	CD	B-NP
O	1051	1061	previously	previously	RB	I-NP
O	1062	1070	reported	report	VBN	I-NP
O	1071	1084	nonsynonymous	nonsynonymous	JJ	I-NP
O	1085	1091	SPINK5	SPINK5	NN	I-NP
O	1092	1096	SNPs	SNP	NNS	I-NP
O	1097	1099	in	in	IN	B-PP
O	1100	1108	Japanese	Japanese	JJ	B-NP
O	1109	1115	atopic	atopic	JJ	I-NP
O	1116	1124	families	family	NNS	I-NP
O	1125	1135	identified	identify	VBN	B-VP
O	1136	1143	through	through	IN	B-PP
O	1144	1153	asthmatic	asthmatic	JJ	B-NP
O	1154	1162	children	child	NNS	I-NP
O	1163	1165	or	or	CC	I-NP
O	1166	1174	subjects	subject	NNS	I-NP
O	1175	1179	with	with	IN	B-PP
O	1180	1186	atopic	atopic	JJ	B-NP
O	1187	1197	dermatitis	dermatitis	NN	I-NP
O	1198	1201	and	and	CC	O
O	1202	1207	found	find	VBD	B-VP
O	1208	1212	that	that	IN	B-SBAR
O	1213	1219	SPINK5	SPINK5	NN	B-NP
O	1220	1223	was	be	VBD	B-VP
O	1224	1234	associated	associate	VBN	I-VP
O	1235	1239	with	with	IN	B-PP
O	1240	1251	development	development	NN	B-NP
O	1252	1254	of	of	IN	B-PP
O	1255	1261	atopic	atopic	JJ	B-NP
O	1262	1272	dermatitis	dermatitis	NN	I-NP
O	1273	1276	but	but	CC	B-NP
O	1277	1280	not	not	RB	I-NP
O	1281	1287	asthma	asthma	NN	B-NP
O	1288	1289	[	[	(	O
O	1289	1291	17	17	CD	B-NP
O	1291	1292	]	]	)	O
O	1292	1293	.	.	.	O

O	1294	1301	Kabesch	Kabesch	NNP	B-NP
O	1302	1303	M	M	NNP	I-NP
O	1304	1306	et	et	FW	I-NP
O	1307	1309	al	al	FW	I-NP
O	1309	1310	.	.	.	O
O	1311	1319	analyzed	analyze	VBN	B-NP
O	1320	1326	G1258A	G1258A	NN	I-NP
O	1327	1328	(	(	(	O
O	1328	1337	Glu420Lys	Glu420Lys	NN	B-NP
O	1337	1338	)	)	)	O
O	1339	1341	in	in	IN	B-PP
O	1342	1343	a	a	DT	B-NP
O	1344	1350	German	German	JJ	I-NP
O	1351	1361	population	population	NN	I-NP
O	1362	1364	of	of	IN	B-PP
O	1365	1371	school	school	NN	B-NP
O	1372	1380	children	child	NNS	I-NP
O	1380	1381	,	,	,	O
O	1382	1385	and	and	CC	O
O	1386	1391	found	find	VBD	B-VP
O	1392	1395	its	its	PRP$	B-NP
O	1396	1407	association	association	NN	I-NP
O	1408	1412	with	with	IN	B-PP
O	1413	1419	asthma	asthma	NN	B-NP
O	1420	1422	as	as	RB	B-CONJP
O	1423	1427	well	well	RB	I-CONJP
O	1428	1430	as	as	IN	I-CONJP
O	1431	1432	a	a	DT	B-NP
O	1433	1444	concomitant	concomitant	JJ	I-NP
O	1445	1455	occurrence	occurrence	NN	I-NP
O	1456	1458	of	of	IN	B-PP
O	1459	1465	asthma	asthma	NN	B-NP
O	1466	1469	and	and	CC	O
O	1470	1476	atopic	atopic	JJ	B-NP
O	1477	1487	dermatitis	dermatitis	NN	I-NP
O	1488	1489	[	[	(	O
O	1489	1491	18	18	CD	B-NP
O	1491	1492	]	]	)	O
O	1492	1493	.	.	.	O

O	1494	1501	However	However	RB	B-ADVP
O	1501	1502	,	,	,	O
O	1503	1506	two	two	CD	B-NP
O	1507	1517	subsequent	subsequent	JJ	I-NP
O	1518	1525	studies	study	NNS	I-NP
O	1526	1532	failed	fail	VBD	B-VP
O	1533	1535	to	to	TO	I-VP
O	1536	1545	replicate	replicate	VB	I-VP
O	1546	1549	the	the	DT	B-NP
O	1550	1558	original	original	JJ	I-NP
O	1559	1565	SPINK5	SPINK5	NN	I-NP
O	1566	1574	findings	finding	NNS	I-NP
O	1575	1578	for	for	IN	B-PP
O	1579	1587	allergic	allergic	JJ	B-NP
O	1588	1596	diseases	disease	NNS	I-NP
O	1597	1598	[	[	(	O
O	1598	1600	19	19	CD	B-NP
O	1600	1601	,	,	,	I-NP
O	1601	1603	20	20	CD	I-NP
O	1603	1604	]	]	)	O
O	1604	1605	.	.	.	O

O	1606	1613	Folster	Folster	NNP	B-NP
O	1613	1614	-	-	HYPH	I-NP
O	1614	1619	Holst	Holst	NNP	I-NP
O	1620	1622	et	et	FW	I-NP
O	1623	1625	al	al	FW	I-NP
O	1626	1635	genotyped	genotype	VBN	B-VP
O	1636	1640	four	four	CD	B-NP
O	1641	1654	nonsynonymous	nonsynonymous	JJ	I-NP
O	1655	1659	SNPs	SNP	NNS	I-NP
O	1660	1661	(	(	(	O
O	1661	1670	Asp106Asn	Asp106Asn	NN	B-NP
O	1670	1671	,	,	,	O
O	1672	1681	Asn368Ser	Asn368Ser	NN	B-NP
O	1681	1682	,	,	,	O
O	1683	1692	Asp386Asn	Asp386Asn	NN	B-NP
O	1692	1693	,	,	,	O
O	1694	1697	and	and	CC	O
O	1698	1707	Glu420Lys	Glu420Lys	NN	B-NP
O	1707	1708	)	)	)	O
O	1708	1709	,	,	,	O
O	1710	1713	and	and	CC	O
O	1714	1722	detected	detect	VBD	B-VP
O	1723	1725	no	no	DT	B-NP
O	1726	1737	association	association	NN	I-NP
O	1738	1745	between	between	IN	B-PP
O	1746	1752	SPINK5	SPINK5	NN	B-NP
O	1753	1756	and	and	CC	O
O	1757	1763	atopic	atopic	JJ	B-NP
O	1764	1774	dermatitis	dermatitis	NN	I-NP
O	1775	1777	in	in	IN	B-PP
O	1778	1789	populations	population	NNS	B-NP
O	1790	1792	of	of	IN	B-PP
O	1793	1801	Northern	Northern	JJ	B-NP
O	1802	1808	German	German	JJ	I-NP
O	1809	1815	origin	origin	NN	I-NP
O	1816	1817	[	[	(	O
O	1817	1819	20	20	CD	B-NP
O	1819	1820	]	]	)	O
O	1820	1821	.	.	.	O

O	1822	1831	Jongepier	Jongepier	NNP	B-NP
O	1832	1833	H	H	NNP	I-NP
O	1834	1836	et	et	FW	I-NP
O	1837	1839	al	al	FW	I-NP
O	1839	1840	.	.	.	O
O	1841	1847	failed	fail	VBD	B-VP
O	1848	1850	to	to	TO	I-VP
O	1851	1857	detect	detect	VB	I-VP
O	1858	1861	any	any	DT	B-NP
O	1862	1873	association	association	NN	I-NP
O	1874	1881	between	between	IN	B-PP
O	1882	1888	SPINK5	SPINK5	NN	B-NP
O	1889	1892	and	and	CC	I-NP
O	1893	1899	asthma	asthma	NN	I-NP
O	1899	1900	,	,	,	O
O	1901	1907	atopic	atopic	JJ	B-NP
O	1908	1918	phenotypes	phenotype	NNS	I-NP
O	1919	1922	and	and	CC	O
O	1923	1929	atopic	atopic	JJ	B-NP
O	1930	1940	dermatitis	dermatitis	NN	I-NP
O	1941	1943	in	in	IN	B-PP
O	1944	1945	a	a	DT	B-NP
O	1946	1951	Dutch	Dutch	JJ	I-NP
O	1952	1962	population	population	NN	I-NP
O	1963	1964	[	[	(	O
O	1964	1966	19	19	CD	B-NP
O	1966	1967	]	]	)	O
O	1967	1968	.	.	.	O

O	1969	1974	These	These	DT	B-NP
O	1975	1985	discordant	discordant	JJ	I-NP
O	1986	1994	findings	finding	NNS	I-NP
O	1995	2003	probably	probably	RB	B-ADVP
O	2004	2011	reflect	reflect	VBP	B-VP
O	2012	2021	different	different	JJ	B-NP
O	2022	2029	genetic	genetic	JJ	I-NP
O	2030	2033	and	and	CC	I-NP
O	2034	2047	environmental	environmental	JJ	I-NP
O	2048	2059	backgrounds	background	NNS	I-NP
O	2060	2062	in	in	IN	B-PP
O	2063	2070	various	various	JJ	B-NP
O	2071	2082	populations	population	NNS	I-NP
O	2082	2083	.	.	.	O

O	2084	2086	To	To	TO	B-VP
O	2087	2096	determine	determine	VB	I-VP
O	2097	2104	whether	whether	IN	B-SBAR
O	2105	2118	nonsynonymous	nonsynonymous	JJ	B-NP
O	2119	2123	SNPs	SNP	NNS	I-NP
O	2124	2126	of	of	IN	B-PP
O	2127	2130	the	the	DT	B-NP
O	2131	2137	SPINK5	SPINK5	NN	I-NP
O	2138	2141	are	be	VBP	B-VP
O	2142	2150	involved	involve	VBN	I-VP
O	2151	2153	in	in	IN	B-PP
O	2154	2157	the	the	DT	B-NP
O	2158	2170	pathogenesis	pathogenesis	NN	I-NP
O	2171	2173	of	of	IN	B-PP
O	2174	2180	asthma	asthma	NN	B-NP
O	2181	2183	in	in	IN	B-PP
O	2184	2187	the	the	DT	B-NP
O	2188	2195	Chinese	Chinese	NNP	I-NP
O	2196	2199	Han	Han	NNP	I-NP
O	2200	2210	population	population	NN	I-NP
O	2210	2211	,	,	,	O
O	2212	2214	we	we	PRP	B-NP
O	2215	2224	performed	perform	VBD	B-VP
O	2225	2226	a	a	DT	B-NP
O	2227	2231	case	case	NN	I-NP
O	2231	2232	-	-	HYPH	B-NP
O	2232	2239	control	control	NN	I-NP
O	2240	2245	study	study	NN	I-NP
O	2246	2248	by	by	IN	B-PP
O	2249	2259	genotyping	genotype	VBG	B-VP
O	2260	2264	four	four	CD	B-NP
O	2265	2278	nonsynonymous	nonsynonymous	JJ	I-NP
O	2279	2283	SNPs	SNP	NNS	I-NP
O	2284	2286	in	in	IN	B-PP
O	2287	2290	the	the	DT	B-NP
O	2291	2297	SPINK5	SPINK5	NN	I-NP
O	2297	2298	.	.	.	O

O	2299	2301	We	We	PRP	B-NP
O	2302	2305	did	do	VBD	B-VP
O	2306	2309	not	not	RB	I-VP
O	2310	2316	detect	detect	VB	I-VP
O	2317	2320	any	any	DT	B-NP
O	2321	2332	significant	significant	JJ	I-NP
O	2333	2344	association	association	NN	I-NP
O	2345	2352	between	between	IN	B-PP
O	2353	2358	these	these	DT	B-NP
O	2359	2372	nonsynonymous	nonsynonymous	JJ	I-NP
O	2373	2377	SNPs	SNP	NNS	I-NP
O	2378	2381	and	and	CC	I-NP
O	2382	2388	asthma	asthma	NN	I-NP
O	2389	2391	in	in	IN	B-PP
O	2392	2395	our	our	PRP$	B-NP
O	2396	2403	Chinese	Chinese	JJ	I-NP
O	2404	2411	samples	sample	NNS	I-NP
O	2411	2412	.	.	.	O

O	2413	2417	With	With	IN	B-PP
O	2418	2421	our	our	PRP$	B-NP
O	2422	2428	sample	sample	NN	I-NP
O	2429	2433	size	size	NN	I-NP
O	2433	2434	,	,	,	O
O	2435	2437	we	we	PRP	B-NP
O	2438	2446	expected	expect	VBD	B-VP
O	2447	2448	a	a	DT	B-NP
O	2449	2454	power	power	NN	I-NP
O	2455	2457	of	of	IN	B-PP
O	2458	2460	at	at	IN	B-NP
O	2461	2466	least	least	JJS	I-NP
O	2467	2469	80	80	CD	I-NP
O	2469	2470	%	%	NN	I-NP
O	2471	2473	in	in	IN	B-PP
O	2474	2483	detecting	detect	VBG	B-VP
O	2484	2486	an	an	DT	B-NP
O	2487	2493	effect	effect	NN	I-NP
O	2494	2496	of	of	IN	B-PP
O	2497	2499	OR	OR	NN	B-NP
O	2500	2501	>	>	SYM	B-NP
O	2501	2502	=	=	SYM	B-NP
O	2502	2503	1	1	CD	I-NP
O	2503	2504	.	.	.	I-NP
O	2504	2505	3	3	CD	I-NP
O	2506	2509	for	for	IN	B-PP
O	2510	2514	each	each	DT	B-NP
O	2515	2517	of	of	IN	B-PP
O	2518	2523	these	these	DT	B-NP
O	2524	2528	SNPs	SNP	NNS	I-NP
O	2528	2529	.	.	.	O

O	2530	2539	Therefore	Therefore	RB	B-ADVP
O	2539	2540	,	,	,	O
O	2541	2544	our	our	PRP$	B-NP
O	2545	2552	failure	failure	NN	I-NP
O	2553	2555	to	to	TO	B-VP
O	2556	2562	detect	detect	VB	I-VP
O	2563	2565	an	an	DT	B-NP
O	2566	2577	association	association	NN	I-NP
O	2578	2581	for	for	IN	B-PP
O	2582	2587	these	these	DT	B-NP
O	2588	2589	4	4	CD	I-NP
O	2590	2594	SNPs	SNP	NNS	I-NP
O	2595	2598	was	be	VBD	B-VP
O	2599	2602	not	not	RB	O
O	2603	2606	due	due	JJ	B-ADJP
O	2607	2609	to	to	TO	B-PP
O	2610	2613	the	the	DT	B-NP
O	2614	2620	sample	sample	NN	I-NP
O	2621	2625	size	size	NN	I-NP
O	2625	2626	.	.	.	O

O	2627	2632	These	These	DT	B-NP
O	2633	2640	results	result	NNS	I-NP
O	2641	2648	suggest	suggest	VBP	B-VP
O	2649	2653	that	that	IN	B-SBAR
O	2654	2657	the	the	DT	B-NP
O	2658	2671	polymorphisms	polymorphism	NNS	I-NP
O	2672	2674	in	in	IN	B-PP
O	2675	2678	the	the	DT	B-NP
O	2679	2685	coding	cod	VBG	I-NP
O	2686	2692	region	region	NN	I-NP
O	2693	2695	of	of	IN	B-PP
O	2696	2699	the	the	DT	B-NP
O	2700	2706	SPINK5	SPINK5	NN	I-NP
O	2707	2710	are	be	VBP	B-VP
O	2711	2719	unlikely	unlikely	JJ	B-ADJP
O	2720	2722	to	to	TO	B-VP
O	2723	2733	contribute	contribute	VB	I-VP
O	2734	2736	to	to	TO	B-PP
O	2737	2743	asthma	asthma	NN	B-NP
O	2744	2748	risk	risk	NN	I-NP
O	2749	2751	in	in	IN	B-PP
O	2752	2755	the	the	DT	B-NP
O	2756	2763	Chinese	Chinese	NNP	I-NP
O	2764	2767	Han	Han	NNP	I-NP
O	2768	2778	population	population	NN	I-NP
O	2778	2779	.	.	.	O

O	2780	2787	However	However	RB	B-ADVP
O	2787	2788	,	,	,	O
O	2789	2796	because	because	IN	B-SBAR
O	2797	2800	our	our	PRP$	B-NP
O	2801	2809	patients	patient	NNS	I-NP
O	2810	2814	were	be	VBD	B-VP
O	2815	2826	ascertained	ascertain	VBN	I-VP
O	2827	2830	for	for	IN	B-PP
O	2831	2837	asthma	asthma	NN	B-NP
O	2837	2838	,	,	,	O
O	2839	2841	we	we	PRP	B-NP
O	2842	2847	could	could	MD	B-VP
O	2848	2851	not	not	RB	I-VP
O	2852	2859	exclude	exclude	VB	I-VP
O	2860	2861	a	a	DT	B-NP
O	2862	2866	role	role	NN	I-NP
O	2867	2869	of	of	IN	B-PP
O	2870	2873	the	the	DT	B-NP
O	2874	2880	coding	cod	VBG	I-NP
O	2881	2885	SNPs	SNP	NNS	I-NP
O	2886	2888	of	of	IN	B-PP
O	2889	2892	the	the	DT	B-NP
O	2893	2899	SPINK5	SPINK5	NN	I-NP
O	2900	2902	in	in	IN	B-PP
O	2903	2909	atopic	atopic	JJ	B-NP
O	2910	2920	dermatitis	dermatitis	NN	I-NP
O	2921	2923	in	in	IN	B-PP
O	2924	2927	our	our	PRP$	B-NP
O	2928	2938	population	population	NN	I-NP
O	2938	2939	.	.	.	O

O	2940	2943	The	The	DT	B-NP
O	2944	2954	variations	variation	NNS	I-NP
O	2955	2957	in	in	IN	B-PP
O	2958	2961	the	the	DT	B-NP
O	2962	2972	regulatory	regulatory	JJ	I-NP
O	2973	2982	sequences	sequence	NNS	I-NP
O	2983	2985	of	of	IN	B-PP
O	2986	2991	genes	gene	NNS	B-NP
O	2992	2995	may	may	MD	B-VP
O	2996	3005	determine	determine	VB	I-VP
O	3006	3011	risks	risk	NNS	B-NP
O	3012	3014	to	to	TO	B-PP
O	3015	3021	common	common	JJ	B-NP
O	3022	3030	diseases	disease	NNS	I-NP
O	3031	3033	by	by	IN	B-PP
O	3034	3041	causing	cause	VBG	B-VP
O	3042	3051	different	different	JJ	B-NP
O	3052	3058	levels	level	NNS	I-NP
O	3059	3061	of	of	IN	B-PP
O	3062	3072	expression	expression	NN	B-NP
O	3072	3073	.	.	.	O

O	3074	3083	Therefore	Therefore	RB	B-ADVP
O	3083	3084	,	,	,	O
O	3085	3088	the	the	DT	B-NP
O	3089	3103	identification	identification	NN	I-NP
O	3104	3107	and	and	CC	I-NP
O	3108	3118	functional	functional	JJ	I-NP
O	3119	3129	evaluation	evaluation	NN	I-NP
O	3130	3132	of	of	IN	B-PP
O	3133	3146	polymorphisms	polymorphism	NNS	B-NP
O	3147	3149	in	in	IN	B-PP
O	3150	3158	promoter	promoter	NN	B-NP
O	3159	3165	region	region	NN	I-NP
O	3166	3169	are	be	VBP	B-VP
O	3170	3172	of	of	IN	B-PP
O	3173	3178	great	great	JJ	B-NP
O	3179	3184	value	value	NN	I-NP
O	3185	3187	in	in	IN	B-PP
O	3188	3201	understanding	understand	VBG	B-VP
O	3202	3205	the	the	DT	B-NP
O	3206	3213	genetic	genetic	JJ	I-NP
O	3214	3228	susceptibility	susceptibility	NN	I-NP
O	3229	3231	to	to	TO	B-PP
O	3232	3238	asthma	asthma	NN	B-NP
O	3238	3239	.	.	.	O

O	3240	3242	In	In	IN	B-SBAR
O	3243	3248	order	order	NN	O
O	3249	3251	to	to	TO	B-VP
O	3252	3261	determine	determine	VB	I-VP
O	3262	3265	the	the	DT	B-NP
O	3266	3270	role	role	NN	I-NP
O	3271	3273	of	of	IN	B-PP
O	3274	3277	the	the	DT	B-NP
O	3278	3284	SPINK5	SPINK5	NN	I-NP
O	3285	3293	promoter	promoter	NN	I-NP
O	3294	3306	polymorphism	polymorphism	NN	I-NP
O	3307	3309	in	in	IN	B-PP
O	3310	3313	the	the	DT	B-NP
O	3314	3326	pathogenesis	pathogenesis	NN	I-NP
O	3327	3329	of	of	IN	B-PP
O	3330	3336	asthma	asthma	NN	B-NP
O	3336	3337	,	,	,	O
O	3338	3340	we	we	PRP	B-NP
O	3341	3350	genotyped	genotype	VBD	B-VP
O	3351	3352	a	a	DT	B-NP
O	3353	3361	promoter	promoter	NN	I-NP
O	3362	3374	polymorphism	polymorphism	NN	I-NP
O	3374	3375	,	,	,	O
O	3376	3377	-	-	HYPH	B-NP
O	3377	3381	206G	206G	NN	I-NP
O	3381	3382	>	>	SYM	I-NP
O	3382	3383	A	A	NN	I-NP
O	3383	3384	,	,	,	O
O	3385	3387	in	in	IN	B-PP
O	3388	3391	422	422	CD	B-NP
O	3392	3398	asthma	asthma	NN	I-NP
O	3399	3407	patients	patient	NNS	I-NP
O	3408	3411	and	and	CC	O
O	3412	3415	410	410	CD	B-NP
O	3416	3424	controls	control	NNS	I-NP
O	3424	3425	,	,	,	O
O	3426	3429	and	and	CC	O
O	3430	3435	found	find	VBD	B-VP
O	3436	3437	a	a	DT	B-NP
O	3438	3446	marginal	marginal	JJ	I-NP
O	3447	3458	association	association	NN	I-NP
O	3458	3459	.	.	.	O

O	3460	3463	The	The	DT	B-NP
O	3464	3473	frequency	frequency	NN	I-NP
O	3474	3476	of	of	IN	B-PP
O	3477	3483	allele	allele	NN	B-NP
O	3484	3485	G	G	NN	I-NP
O	3486	3489	was	be	VBD	B-VP
O	3490	3503	significantly	significantly	RB	B-ADJP
O	3504	3510	higher	high	JJR	I-ADJP
O	3511	3513	in	in	IN	B-PP
O	3514	3523	asthmatic	asthmatic	JJ	B-NP
O	3524	3532	patients	patient	NNS	I-NP
O	3533	3537	than	than	IN	B-PP
O	3538	3542	that	that	DT	B-NP
O	3543	3545	in	in	IN	B-PP
O	3546	3554	controls	control	NNS	B-NP
O	3555	3556	(	(	(	O
O	3556	3557	p	p	NN	B-NP
O	3558	3559	=	=	SYM	B-VP
O	3560	3561	0	0	CD	B-NP
O	3561	3562	.	.	SYM	I-NP
O	3562	3565	022	022	CD	I-NP
O	3565	3566	)	)	)	O
O	3566	3567	.	.	.	O

O	3568	3570	To	To	TO	B-VP
O	3571	3578	confirm	confirm	VB	I-VP
O	3579	3582	the	the	DT	B-NP
O	3583	3594	association	association	NN	I-NP
O	3594	3595	,	,	,	O
O	3596	3606	additional	additional	JJ	B-NP
O	3607	3610	267	267	CD	I-NP
O	3611	3617	asthma	asthma	NN	I-NP
O	3618	3626	patients	patient	NNS	I-NP
O	3627	3630	and	and	CC	O
O	3631	3634	301	301	CD	B-NP
O	3635	3643	controls	control	NNS	I-NP
O	3644	3649	newly	newly	RB	B-VP
O	3650	3659	recruited	recruit	VBN	I-VP
O	3660	3664	from	from	IN	B-PP
O	3665	3668	the	the	DT	B-NP
O	3669	3673	same	same	JJ	I-NP
O	3674	3682	hospital	hospital	NN	I-NP
O	3683	3687	were	be	VBD	B-VP
O	3688	3697	genotyped	genotype	VBN	I-VP
O	3697	3698	,	,	,	O
O	3699	3702	and	and	CC	O
O	3703	3706	the	the	DT	B-NP
O	3707	3708	-	-	HYPH	I-NP
O	3708	3712	206G	206G	NN	I-NP
O	3712	3713	>	>	SYM	I-NP
O	3713	3714	A	A	NN	I-NP
O	3715	3727	polymorphism	polymorphism	NN	I-NP
O	3728	3736	remained	remain	VBD	B-VP
O	3737	3750	significantly	significantly	RB	I-VP
O	3751	3761	associated	associate	VBN	I-VP
O	3762	3766	with	with	IN	B-PP
O	3767	3773	asthma	asthma	NN	B-NP
O	3774	3775	(	(	(	O
O	3775	3776	P	P	NN	B-NP
O	3777	3778	=	=	SYM	B-VP
O	3779	3780	0	0	CD	B-NP
O	3780	3781	.	.	SYM	I-NP
O	3781	3784	001	001	CD	I-NP
O	3784	3785	)	)	)	O
O	3785	3786	,	,	,	O
O	3787	3791	even	even	RB	B-ADVP
O	3792	3797	after	after	IN	B-SBAR
O	3798	3808	Bonferroni	Bonferroni	NNP	B-NP
O	3809	3819	correction	correction	NN	I-NP
O	3819	3820	(	(	(	O
O	3820	3828	adjusted	adjust	VBN	B-NP
O	3829	3830	P	P	NN	I-NP
O	3831	3832	=	=	SYM	B-VP
O	3833	3834	0	0	CD	B-NP
O	3834	3835	.	.	SYM	I-NP
O	3835	3837	01	01	CD	I-NP
O	3837	3838	)	)	)	O
O	3838	3839	.	.	.	O

O	3840	3842	To	To	TO	B-PP
O	3843	3846	our	our	PRP$	B-NP
O	3847	3856	knowledge	knowledge	NN	I-NP
O	3856	3857	,	,	,	O
O	3858	3862	this	this	DT	B-NP
O	3863	3865	is	be	VBZ	B-VP
O	3866	3869	the	the	DT	B-NP
O	3870	3875	first	first	JJ	I-NP
O	3876	3882	report	report	NN	I-NP
O	3883	3885	of	of	IN	B-PP
O	3886	3888	an	an	DT	B-NP
O	3889	3900	association	association	NN	I-NP
O	3901	3903	of	of	IN	B-PP
O	3904	3905	-	-	HYPH	B-NP
O	3905	3909	206G	206G	NN	I-NP
O	3909	3910	>	>	SYM	I-NP
O	3910	3911	A	A	NN	I-NP
O	3912	3924	polymorphism	polymorphism	NN	I-NP
O	3925	3929	with	with	IN	B-PP
O	3930	3936	asthma	asthma	NN	B-NP
O	3936	3937	.	.	.	O

O	3938	3940	We	We	PRP	B-NP
O	3941	3948	further	further	RB	B-ADVP
O	3949	3957	examined	examine	VBD	B-VP
O	3958	3961	the	the	DT	B-NP
O	3962	3971	potential	potential	JJ	I-NP
O	3972	3982	functional	functional	JJ	I-NP
O	3983	3987	role	role	NN	I-NP
O	3988	3990	of	of	IN	B-PP
O	3991	3995	this	this	DT	B-NP
O	3996	4004	promoter	promoter	NN	I-NP
O	4005	4017	polymorphism	polymorphism	NN	I-NP
O	4017	4018	,	,	,	O
O	4019	4022	and	and	CC	O
O	4023	4028	found	find	VBD	B-VP
O	4029	4033	that	that	IN	B-SBAR
O	4034	4037	the	the	DT	B-NP
O	4038	4039	G	G	NN	I-NP
O	4040	4042	to	to	TO	B-PP
O	4043	4044	A	A	NN	B-NP
O	4045	4057	substitution	substitution	NN	I-NP
O	4058	4060	at	at	IN	B-PP
O	4061	4062	-	-	SYM	B-NP
O	4062	4065	206	206	CD	I-NP
O	4066	4075	generated	generate	VBD	B-VP
O	4076	4077	a	a	DT	B-NP
O	4078	4082	GATA	GATA	NN	I-NP
O	4082	4083	-	-	HYPH	B-NP
O	4083	4084	3	3	CD	I-NP
O	4085	4098	transcription	transcription	NN	I-NP
O	4099	4105	factor	factor	NN	I-NP
O	4106	4113	binding	binding	NN	I-NP
O	4114	4118	site	site	NN	I-NP
O	4118	4119	.	.	.	O

O	4120	4125	Major	Major	JJ	B-NP
O	4126	4139	transcription	transcription	NN	I-NP
O	4140	4147	factors	factor	NNS	I-NP
O	4148	4159	controlling	control	VBG	B-VP
O	4160	4163	Th1	Th1	NN	B-NP
O	4164	4167	and	and	CC	I-NP
O	4168	4171	Th2	Th2	NN	I-NP
O	4172	4183	development	development	NN	I-NP
O	4183	4184	,	,	,	O
O	4185	4189	such	such	JJ	B-PP
O	4190	4192	as	as	IN	I-PP
O	4193	4194	T	T	NN	B-NP
O	4194	4195	-	-	HYPH	I-NP
O	4195	4198	box	box	NN	I-NP
O	4199	4212	transcription	transcription	NN	I-NP
O	4213	4219	factor	factor	NN	I-NP
O	4220	4223	and	and	CC	O
O	4224	4229	GATA3	GATA3	NN	B-NP
O	4229	4230	,	,	,	O
O	4231	4234	are	be	VBP	B-VP
O	4235	4243	possibly	possibly	RB	I-VP
O	4244	4252	involved	involve	VBN	I-VP
O	4253	4255	in	in	IN	B-PP
O	4256	4262	asthma	asthma	NN	B-NP
O	4263	4266	and	and	CC	O
O	4267	4273	atopic	atopic	JJ	B-NP
O	4274	4282	diseases	disease	NNS	I-NP
O	4282	4283	.	.	.	O

O	4284	4288	GATA	GATA	NN	B-NP
O	4288	4289	-	-	HYPH	B-NP
O	4289	4290	3	3	CD	I-NP
O	4290	4291	,	,	,	O
O	4292	4293	a	a	DT	B-NP
O	4294	4307	transcription	transcription	NN	I-NP
O	4308	4314	factor	factor	NN	I-NP
O	4315	4327	specifically	specifically	RB	B-VP
O	4328	4337	expressed	express	VBN	I-VP
O	4338	4340	in	in	IN	B-PP
B-Cell	4341	4342	T	T	NN	B-NP
I-Cell	4343	4349	helper	helper	NN	I-NP
I-Cell	4350	4351	2	2	CD	I-NP
I-Cell	4352	4353	(	(	(	O
I-Cell	4353	4356	Th2	Th2	NN	B-NP
I-Cell	4356	4357	)	)	)	I-NP
I-Cell	4358	4363	cells	cell	NNS	I-NP
O	4363	4364	,	,	,	O
O	4365	4370	plays	play	VBZ	B-VP
O	4371	4372	a	a	DT	B-NP
O	4373	4381	critical	critical	JJ	I-NP
O	4382	4386	role	role	NN	I-NP
O	4387	4389	in	in	IN	B-PP
O	4390	4393	the	the	DT	B-NP
O	4394	4409	differentiation	differentiation	NN	I-NP
O	4410	4412	of	of	IN	B-PP
B-Cell	4413	4416	Th2	Th2	NN	B-NP
I-Cell	4417	4422	cells	cell	NNS	I-NP
O	4423	4427	from	from	IN	B-PP
O	4428	4439	uncommitted	uncommitted	JJ	B-NP
B-Cell	4440	4443	CD4	CD4	NN	I-NP
I-Cell	4443	4444	+	+	SYM	B-VP
I-Cell	4445	4456	lymphocytes	lymphocyte	NNS	B-NP
O	4456	4457	.	.	.	O

O	4458	4460	In	In	IN	B-PP
O	4461	4469	addition	addition	NN	B-NP
O	4469	4470	,	,	,	O
O	4471	4475	GATA	GATA	NN	B-NP
O	4475	4476	-	-	HYPH	B-NP
O	4476	4477	3	3	CD	I-NP
O	4478	4480	is	be	VBZ	B-VP
O	4481	4490	essential	essential	JJ	B-ADJP
O	4491	4494	for	for	IN	B-PP
O	4495	4498	the	the	DT	B-NP
O	4499	4509	expression	expression	NN	I-NP
O	4510	4512	of	of	IN	B-PP
O	4513	4516	the	the	DT	B-NP
O	4517	4526	cytokines	cytokine	NNS	I-NP
O	4527	4529	IL	IL	NN	I-NP
O	4529	4530	-	-	HYPH	B-NP
O	4530	4531	4	4	CD	I-NP
O	4531	4532	,	,	,	O
O	4533	4535	IL	IL	NN	B-NP
O	4535	4536	-	-	HYPH	I-NP
O	4536	4537	5	5	CD	I-NP
O	4538	4541	and	and	CC	I-NP
O	4542	4544	IL	IL	NN	I-NP
O	4544	4545	-	-	SYM	O
O	4545	4547	13	13	CD	B-NP
O	4548	4552	that	that	WDT	B-NP
O	4553	4560	mediate	mediate	VBP	B-VP
O	4561	4569	allergic	allergic	JJ	B-NP
O	4570	4582	inflammation	inflammation	NN	I-NP
O	4583	4584	[	[	(	O
O	4584	4586	23	23	CD	B-NP
O	4586	4587	]	]	)	O
O	4587	4588	.	.	.	O

O	4589	4592	Our	Our	PRP$	B-NP
O	4593	4603	luciferase	luciferase	NN	I-NP
O	4604	4612	reporter	reporter	NN	I-NP
O	4613	4618	assay	assay	NN	I-NP
O	4619	4628	confirmed	confirm	VBD	B-VP
O	4629	4633	that	that	IN	B-SBAR
O	4634	4637	SNP	SNP	NN	B-NP
O	4638	4639	-	-	HYPH	B-NP
O	4639	4643	206G	206G	NN	I-NP
O	4643	4644	>	>	JJ	I-NP
O	4644	4645	A	A	NN	I-NP
O	4646	4648	is	be	VBZ	B-VP
O	4649	4659	associated	associate	VBN	I-VP
O	4660	4664	with	with	IN	B-PP
O	4665	4668	the	the	DT	B-NP
O	4669	4684	transcriptional	transcriptional	JJ	I-NP
O	4685	4693	activity	activity	NN	I-NP
O	4694	4696	of	of	IN	B-PP
O	4697	4703	SPINK5	SPINK5	NN	B-NP
O	4703	4704	.	.	.	O

O	4705	4708	The	The	DT	B-NP
O	4709	4710	G	G	NN	I-NP
O	4711	4717	allele	allele	NN	I-NP
O	4718	4721	was	be	VBD	B-VP
O	4722	4732	associated	associate	VBN	I-VP
O	4733	4737	with	with	IN	B-PP
O	4738	4747	decreased	decrease	VBN	B-NP
O	4748	4763	transcriptional	transcriptional	JJ	I-NP
O	4764	4772	activity	activity	NN	I-NP
O	4773	4775	of	of	IN	B-PP
O	4776	4779	the	the	DT	B-NP
O	4780	4786	SPINK5	SPINK5	NN	I-NP
O	4786	4787	.	.	.	O

O	4788	4791	The	The	DT	B-NP
O	4792	4801	mechanism	mechanism	NN	I-NP
O	4802	4804	by	by	IN	B-PP
O	4805	4810	which	which	WDT	B-NP
O	4811	4814	the	the	DT	B-NP
O	4815	4816	-	-	HYPH	I-NP
O	4816	4820	206G	206G	NN	I-NP
O	4820	4821	>	>	SYM	I-NP
O	4821	4822	A	A	NN	I-NP
O	4823	4826	SNP	SNP	NN	I-NP
O	4827	4834	affects	affect	VBZ	B-VP
O	4835	4841	SPINK5	SPINK5	NN	B-NP
O	4842	4852	expression	expression	NN	I-NP
O	4853	4856	may	may	MD	B-VP
O	4857	4859	be	be	VB	I-VP
O	4860	4869	explained	explain	VBN	I-VP
O	4870	4872	by	by	IN	B-PP
O	4873	4876	the	the	DT	B-NP
O	4877	4886	potential	potential	JJ	I-NP
O	4887	4899	differential	differential	JJ	I-NP
O	4900	4913	transcription	transcription	NN	I-NP
O	4914	4920	factor	factor	NN	I-NP
O	4921	4928	binding	binding	NN	I-NP
O	4929	4931	of	of	IN	B-PP
O	4932	4936	GATA	GATA	NN	B-NP
O	4937	4944	binding	binding	NN	I-NP
O	4945	4951	factor	factor	NN	I-NP
O	4951	4952	,	,	,	O
O	4953	4958	since	since	IN	B-SBAR
O	4959	4960	-	-	HYPH	B-NP
O	4960	4964	206G	206G	NN	I-NP
O	4964	4965	>	>	JJ	I-NP
O	4965	4966	A	A	NN	I-NP
O	4967	4969	is	be	VBZ	B-VP
O	4970	4977	located	located	JJ	B-ADJP
O	4978	4980	at	at	IN	B-PP
O	4981	4984	the	the	DT	B-NP
O	4985	4989	core	core	NN	I-NP
O	4990	4998	sequence	sequence	NN	I-NP
O	4999	5001	of	of	IN	B-PP
O	5002	5006	GATA	GATA	NN	B-NP
O	5007	5014	binding	binding	NN	I-NP
O	5015	5021	factor	factor	NN	I-NP
O	5022	5029	binding	binding	NN	I-NP
O	5030	5034	site	site	NN	I-NP
O	5034	5035	.	.	.	O

O	5036	5051	Electrophoretic	Electrophoretic	JJ	B-NP
O	5052	5060	mobility	mobility	NN	I-NP
O	5061	5066	shift	shift	NN	I-NP
O	5067	5072	assay	assay	NN	I-NP
O	5073	5082	confirmed	confirm	VBD	B-VP
O	5083	5087	that	that	IN	B-SBAR
O	5088	5091	the	the	DT	B-NP
O	5092	5093	A	A	NN	I-NP
O	5094	5096	to	to	TO	B-PP
O	5097	5098	G	G	NN	B-NP
O	5099	5111	substitution	substitution	NN	I-NP
O	5112	5114	at	at	IN	B-PP
O	5115	5116	-	-	SYM	B-NP
O	5116	5119	206	206	CD	I-NP
O	5120	5133	significantly	significantly	RB	B-ADVP
O	5134	5141	reduced	reduce	VBD	B-VP
O	5142	5145	the	the	DT	B-NP
O	5146	5153	binding	bind	VBG	I-NP
O	5154	5164	efficiency	efficiency	NN	I-NP
O	5165	5167	of	of	IN	B-PP
B-Cellular_component	5168	5175	nuclear	nuclear	JJ	B-NP
O	5176	5184	proteins	protein	NNS	I-NP
O	5185	5187	to	to	TO	B-PP
O	5188	5192	this	this	DT	B-NP
O	5193	5200	element	element	NN	I-NP
O	5200	5201	.	.	.	O

O	5202	5205	Our	Our	PRP$	B-NP
O	5206	5210	data	datum	NNS	I-NP
O	5211	5218	suggest	suggest	VBP	B-VP
O	5219	5223	that	that	IN	B-SBAR
O	5224	5228	loss	loss	NN	B-NP
O	5229	5231	of	of	IN	B-PP
O	5232	5236	GATA	GATA	NN	B-NP
O	5237	5250	transcription	transcription	NN	I-NP
O	5251	5257	factor	factor	NN	I-NP
O	5258	5268	regulation	regulation	NN	I-NP
O	5269	5273	with	with	IN	B-PP
O	5274	5277	the	the	DT	B-NP
O	5278	5279	-	-	HYPH	I-NP
O	5279	5283	206G	206G	NN	I-NP
O	5284	5287	may	may	MD	B-VP
O	5288	5296	decrease	decrease	VB	I-VP
O	5297	5300	the	the	DT	B-NP
O	5301	5307	SPINK5	SPINK5	NN	I-NP
O	5308	5318	expression	expression	NN	I-NP
O	5319	5322	and	and	CC	O
O	5323	5330	thereby	thereby	RB	B-VP
O	5331	5342	potentially	potentially	RB	I-VP
O	5343	5350	perturb	perturb	VB	I-VP
O	5351	5354	the	the	DT	B-NP
O	5355	5372	immunosuppressive	immunosuppressive	JJ	I-NP
O	5373	5381	function	function	NN	I-NP
O	5382	5384	of	of	IN	B-PP
O	5385	5390	LEKTI	LEKTI	NN	B-NP
O	5390	5391	.	.	.	O

